Vivo Capital
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Vivo Capital Information
Geographic Data
Address: 575 High St Ste 201
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
2,761,045Website Global Rank
6,244Website Monthly Traffic
Twitter Followers
Description
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Contact Phone:
+16506880818
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2018 | TOT BIOPHARM | Series B | 102M |
| 12/2020 | Provivi | Series C | 0 |
| 3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
| 4/2011 | Eiger BioPharmaceuticals | Series A | 14.5M |
| 11/2007 | Carbylan Therapeutics | Series B | 20M |
| 6/2010 | Vicept Therapeutics | Series A | 16M |
| 7/2018 | Sinovac Biotech | Post-IPO Equity | 86.7M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 1/2019 | Innocare | Private Equity Round | 0 |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 3/2023 | EpiBiologics | Series A | 0 |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 2/2021 | Innocare | Post-IPO Equity | - |
| 9/2014 | AirXpanders | Series E | 1M |
| 4/2012 | AirXpanders | Series D | 11M |
| 1/2012 | AirXpanders | Series D | 10.3M |
| 9/2018 | AirXpanders | Post-IPO Equity | 15M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 1/2021 | Serán Bioscience | Venture Round | - |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 1/2013 | Carbylan Therapeutics | Venture Round | 6M |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
| 6/2012 | Ceptaris Therapeutics | Series D | 10M |
| 10/2014 | Aclaris Therapeutics | Series B | 21M |
| 12/2009 | Revance Therapeutics | Series D | 0 |
| 4/2004 | Revance Therapeutics | Series B | 13M |
| 4/2018 | Poseida Therapeutics | Series B | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 1/2000 | Med-eCommerce.com | Venture Round | 2M |
| 11/2002 | Copernicus Therapeutics | Venture Round | 2M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 7/2015 | Gengmei | Series B | - |
| 5/2021 | Scientia Vascular | Private Equity Round | 50M |
| 2/2021 | ASLAN Pharmaceuticals | Post-IPO Equity | 18M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 1/2005 | NextWave Pharmaceuticals | Series A | 10M |
| 2/2003 | AgraQuest | Venture Round | 9.4M |
| 11/2011 | Medley Health | Series A | 20M |
| 8/2017 | Amyris | Post-IPO Equity | 50M |
| 1/2015 | Synapse Biomedical | Venture Round | - |
| 2/2018 | Innocare | Private Equity Round | 55M |
| 6/2018 | Cerebral Therapeutics | Series A | 3M |
| 9/2008 | Sagent Pharmaceuticals | Series A | 30M |
| 9/2007 | Sagent Pharmaceuticals | Series A | 53M |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2017 | OMNI | Series C | - |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 7/2022 | Tebra | Series B | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 8/2008 | InteKrin | Series C | 0 |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 12/2022 | Ronovo Surgical | Series B | - |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
| 6/2017 | Platelet BioGenesis | Series A | 0 |
| 1/2007 | InteKrin | Series B | 0 |
| 11/2019 | Genetron Health | Series D | 71M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 7/2016 | Tricida | Series C | 0 |
| 3/2023 | Unicycive Therapeutics | Post-IPO Equity | 0 |
| 6/2013 | AirXpanders | Series E | 9M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 2/2020 | ALX Oncology | Series C | 105M |
| 4/2021 | Sera Prognostics | Series E | 0 |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 11/2007 | Ceptaris Therapeutics | Series C | 14.5M |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 6/2012 | SentreHEART | Series C | 26M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 9/2019 | Passage Bio | Series B | 110M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 9/2021 | Attralus | Series B | 116M |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 11/2017 | Tricida | Series D | 0 |
| 12/2004 | Prestwick Pharmaceuticals | Series B | 37M |
| 2/2009 | Eiger BioPharmaceuticals | Series A | 8.3M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 5/2021 | Aerobiotix | Venture Round | 0 |
| 1/2010 | Neomend | Series D | 30M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 6/2009 | Sagent | Series A | 30M |
| 7/2019 | IGM Biosciences | Series C | 102M |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 6/2003 | Prestwick Pharmaceuticals | Series A | 15M |
| 10/2003 | Cotherix | Series C | 55M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 2/2007 | NextWave Pharmaceuticals | Series B | 40M |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 8/2007 | Prestwick Pharmaceuticals | Venture Round | 20M |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 4/2021 | Ronovo Surgical | Series A | - |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 10/2022 | Neocis | Series D | 0 |
| 8/2020 | PatientPop | Series C | 50M |
| 11/2015 | VYNE Therapeutics | Series B | 45M |
| 5/2021 | Rgenta Therapeutics | Seed Round | 18M |
| 10/2019 | dMed | Series B | 50M |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 3/2021 | Ossium Health | Series B | 63M |
| 10/2020 | Neocis | Series D | 72M |
| 3/2019 | MacuLogix | Series D | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 7/2020 | Preventice Solutions | Series B | 0 |
| 3/2019 | Cerebral Therapeutics | Series A | 7.8M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 9/2016 | ReadCoor | Series A | 23M |
| 6/2011 | Revance Therapeutics | Series D | 45M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 9/2018 | Immune-Onc Therapeutics | Series B | 33M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 10/2006 | Prestwick Pharmaceuticals | Series C | 60M |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 11/2018 | Visen Pharmaceuticals | Series A | 0 |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 11/2017 | Medeor Therapeutics | Series B | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 7/2020 | Citrine Medicine | Series A | 0 |
| 5/2021 | Esco Lifesciences | Series A | 0 |
| 10/2012 | Aclaris Therapeutics | Series A | 21M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 6/2017 | Zai Lab | Series C | 30M |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 9/2016 | SentreHEART | Series D | 35M |
| 6/2021 | RayzeBio | Series C | 108M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 4/2020 | Legend Biotech | Series A | 0 |
| 5/2017 | Aadi | Series A | 23M |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 5/2004 | CAPNIA | Series B | 12M |
| 12/2022 | Pulmocide | Series C | 0 |
| 2/2019 | Bolt | Series B | 54M |
| 9/2021 | INBRACE | Series D | 0 |
| 11/2022 | Bonum | Series A | 93M |
| 11/2004 | ViOptix | Series C | 0 |
| 12/2007 | Revance Therapeutics | Series C | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 3/2017 | Angiotech Pharmaceuticals | Venture Round | - |
| 10/2020 | Olema Oncology | Series C | 85M |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 10/2019 | INBRACE | Series C | 45M |
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 9/2017 | Kadmon | Post-IPO Equity | 80.4M |
| 3/2021 | OMNI | Series D | - |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 8/2022 | Klavi | Series A | 15M |
| 12/2020 | dMed | Series C | 100M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
